BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2386542)

  • 21. Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium.
    Pitts WJ; Jetter JW; Pinto DJ; Orwat MJ; Batt DG; Sherk SR; Petraitis JJ; Jacobson IC; Copeland RA; Dowling RL; Jaffee BD; Gardner TL; Jones EA; Magolda RL
    Bioorg Med Chem Lett; 1998 Feb; 8(3):307-12. PubMed ID: 9871675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.
    Vyas VK; Variya B; Ghate MD
    Eur J Med Chem; 2014 Jul; 82():385-93. PubMed ID: 24929289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
    He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
    Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects?
    Ullrich A; Knecht W; Fries M; Löffler M
    Eur J Biochem; 2001 Mar; 268(6):1861-8. PubMed ID: 11248707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
    Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
    J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors.
    DeFrees SA; Sawick DP; Cunningham B; Heinstein PF; Morré DJ; Cassady JM
    Biochem Pharmacol; 1988 Oct; 37(20):3807-16. PubMed ID: 2847745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular pharmacology of DUP-785, a new anticancer agent.
    Anderson LW; Strong JM; Cysyk RL
    Cancer Commun; 1989; 1(6):381-7. PubMed ID: 2562006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans.
    Zameitat E; Gojković Z; Knecht W; Piskur J; Löffler M
    FEBS J; 2006 Jul; 273(14):3183-91. PubMed ID: 16774642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The "anti-pyrimidine effect" of hypoxia and brequinar sodium (NSC 368390) is of consequence for tumor cell growth.
    Löffler M
    Biochem Pharmacol; 1992 May; 43(10):2281-7. PubMed ID: 1599514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program.
    Cleaveland ES; Monks A; Vaigro-Wolff A; Zaharevitz DW; Paull K; Ardalan K; Cooney DA; Ford H
    Biochem Pharmacol; 1995 Mar; 49(7):947-54. PubMed ID: 7741767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.
    Schwartsmann G; Peters GJ; Laurensse E; de Waal FC; Loonen AH; Leyva A; Pinedo HM
    Biochem Pharmacol; 1988 Sep; 37(17):3257-66. PubMed ID: 2840910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
    Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
    Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent human dihydroorotate dehydrogenase inhibitory activity of new quinoline-4-carboxylic acids derived from phenolic aldehydes: Synthesis, cytotoxicity, lipophilicity and molecular docking studies.
    Petrović MM; Roschger C; Chaudary S; Zierer A; Mladenović M; Jakovljević K; Marković V; Botta B; Joksović MD
    Bioorg Chem; 2020 Dec; 105():104373. PubMed ID: 33074120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain.
    Hansen M; Le Nours J; Johansson E; Antal T; Ullrich A; Löffler M; Larsen S
    Protein Sci; 2004 Apr; 13(4):1031-42. PubMed ID: 15044733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
    Braakhuis BJ; van Dongen GA; Peters GJ; van Walsum M; Snow GB
    Cancer Lett; 1990 Feb; 49(2):133-7. PubMed ID: 2306706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
    Gehlot P; Vyas VK
    Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
    Schwartsmann G; Dodion P; Vermorken JB; ten Bokkel Huinink WW; Joggi J; Winograd B; Gall H; Simonetti G; van der Vijgh WJ; van Hennik MB
    Cancer Chemother Pharmacol; 1990; 25(5):345-51. PubMed ID: 2306795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
    McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
    Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design.
    Vyas VK; Qureshi G; Oza D; Patel H; Parmar K; Patel P; Ghate MD
    Bioorg Med Chem Lett; 2019 Apr; 29(7):917-922. PubMed ID: 30738663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold.
    Lolli ML; Giorgis M; Tosco P; Foti A; Fruttero R; Gasco A
    Eur J Med Chem; 2012 Mar; 49():102-9. PubMed ID: 22245049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.